Cargando…

Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI

This study aimed to differentiate isocitrate dehydrogenase (IDH) mutation status with the voxel-wise clustering method of multiparametric magnetic resonance imaging (MRI) and to discover biological underpinnings of the clusters. A total of 69 patients with treatment-naïve diffuse glioma were scanned...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagiwara, Akifumi, Tatekawa, Hiroyuki, Yao, Jingwen, Raymond, Catalina, Everson, Richard, Patel, Kunal, Mareninov, Sergey, Yong, William H., Salamon, Noriko, Pope, Whitney B., Nghiemphu, Phioanh L., Liau, Linda M., Cloughesy, Timothy F., Ellingson, Benjamin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776874/ https://www.ncbi.nlm.nih.gov/pubmed/35058510 http://dx.doi.org/10.1038/s41598-022-05077-2

Ejemplares similares

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
por: Tatekawa, Hiroyuki, et al.
Publicado: (2021)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study
por: Yao, Jingwen, et al.
Publicado: (2020)

“Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging
por: Hagiwara, Akifumi, et al.
Publicado: (2021)

Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study
por: Yao, Jingwen, et al.
Publicado: (2022)

Improving B(0) Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation
por: Yao, Jingwen, et al.
Publicado: (2018)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
por: Chakhoyan, Ararat, et al.
Publicado: (2019)

Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI)
por: Wang, Chencai, et al.
Publicado: (2021)

Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks
por: Wang, Chencai, et al.
Publicado: (2022)

Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
por: Patel, Kunal S., et al.
Publicado: (2020)

Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas
por: Cho, Nicholas S., et al.
Publicado: (2023)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas
por: Hosur, Bharat, et al.
Publicado: (2022)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
por: Shidoh, Satoka, et al.
Publicado: (2022)

Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease
por: Goldman, Jodi, et al.
Publicado: (2022)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
por: Banerjee, Pia, et al.
Publicado: (2015)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
por: Van Dyk, Kathleen, et al.
Publicado: (2022)

The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
por: Cho, Nicholas S., et al.
Publicado: (2023)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
por: Liu, Liang Yen, et al.
Publicado: (2019)

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients
por: Liu, Vicki, et al.
Publicado: (2023)

Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas
por: Sahu, Arpita, et al.
Publicado: (2022)

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma
por: Chang, Warren, et al.
Publicado: (2015)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab
por: Leu, Kevin, et al.
Publicado: (2014)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
por: Lu, Victor M, et al.
Publicado: (2018)

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients
por: Auezova, Raushan, et al.
Publicado: (2019)

Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma
por: Jia, Yanfei, et al.
Publicado: (2020)

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tsaphg37g895j8r0e91ehq8f9m